Vice President, Patient Health Impact Rare Disease
Bhash Parasuraman leads the health economics, pricing and market access groups for the Rare Disease BU at Pfizer, where she manages the breadth of the portfolio from inline to very early state pipeline products. She has over 20 years of experience in market access and outcomes, globally and regionally across several therapeutic areas. In her previous role at Pfizer, Bhash was the BU lead for Global Health and Value where she led and managed cross functional teams across the Innovative Pharma BU to support Pfizer’s key assets and business priorities leading to improving access to patients. Prior to joining Pfizer, Bhash spent 13 years at Astra Zeneca, where she took positions of increasing responsibility and led regulatory submissions and negotiations on patient reported outcomes endpoints, and submissions of reimbursement dossiers with HTAs and national payers across several markets. In that capacity, she collaborated with US payers including state Medicaid, as well as key HTA bodies ex US. Bhash has also worked on the payer side with Blue Cross Blue Shield of North Carolina. Bhash has served on several external advisory committees and industry led consortiums, such as the FDA and Critical Path Institute consortium on Patient Reported Outcomes, NCQA to assess and modify HEDIS measurements in respiratory diseases, NCCN to build RWD capabilities to improve adherence to treatment guidelines in oncology. She is currently on the Duke Margolis Working Group on Value Based Payments for Transformative Therapies, and partners closely with US payers, advocacy groups and HTAs on the assessment of value for gene therapies. She has extensively partnered with advocacy groups in pediatric diseases to develop measurements and endpoints to be used in clinical trials, establishing disease management programs and guidelines, and improving access. Bhash has presented extensively at professional conferences and published in several peer-reviewed journals. Bhash has a Pharmacy degree from Birla Institute of Technology, India and a PhD in Pharmacy Administration from University of Louisiana, Monroe.
None yet.